Building on earlier work, University of Maryland researchers show that their nasal spray vaccine can be developed to produce broad and long-lasting protection
Image Credit: NIAID
Every year, new strains of flu emerge, and vaccines must be reformulated to keep up. Researchers at the University of Maryland are making progress toward a different goal: a universal influenza vaccine that protects against many strains with a single nasal spray. In a study published on November 16, 2026, in The Journal of Clinical Investigation, the team showed that their experimental vaccine protected mice against several influenza A subtypes, including H5N1 avian influenza.
“This new development is very exciting for us, because a universal vaccine for influenza that can be delivered through a nasal spray would be easy to deliver and could protect billions of people around the world,” said Xiaoping Zhu, a professor and chair of UMD’s Department of Veterinary Medicine.
The work builds on Zhu’s earlier research on nasal vaccines using a natural protein in all mammals called neonatal Fc receptor (FcRn), that carries antibodies into the cells lining the lungs, throat and nasal passages.
That earlier work used a complete protein called Hemagglutinin from a flu virus to trigger the immune system into making antibodies. But because the head of the protein mutates fast with each new variety, a vaccine built on the full protein would not provide a universal protection.
In the new study, the team removed the head of the protein and used the FcRn transport system to shuttle the remaining portion, the “stalk,” into nasal passage cells of healthy mice. The stalk, which changes far less from strain to strain, has long been viewed as an attractive universal flu vaccine target, but the immune system tends to overlook it. To boost the immune response, Zhu and his colleagues fused the stalk to an antibody fragment. Once FcRn transported the stalk into the body across the nasal passages of mice, the antibody fragment taught their immune systems to recognize the stalk and launch an immune response against a broad range of variants that have the same or similar stalk.
Although scientists have been searching for a universal flu vaccine, many candidates are injected into muscle or skin and are designed to trigger immunity in the blood. A nasal vaccine would build immunity directly in the airways, where flu infections begin, thus halting infection before it has a chance to even enter the bloodstream.
In laboratory trials, mice immunized with this new method survived lethal challenges with H5N1 (90%), H1N1 (91%) and H6N2 (80%). Survival in control groups ranged from 0% to 27.3%. In addition, antibodies were still detectable 16 months after the final dose, and 80% of mice survived a lethal H5N1 dose six months after vaccination.
The vaccine protected against group 1 influenza A viruses, but not against the group 2 H3N2 subtype, so the team plans to add stalks from group 2 and influenza B viruses and to explore combining them to create a multivalent nasal vaccine.
The study was conducted in mice, and Zhu said he hopes to move toward clinical trials to test the safety and effectiveness in humans soon.
---------
The paper, “Mucosal vaccination with hemagglutinin stalk provides broad protection against influenza virus subtypes in mice,” was authored by Weizhong Li, Arunraj M. Rajendrakumar, ZiZhen Miao, Bibek Dhakal, Bogdan M. Domrachev, Tao Wang, Qiuqi Kan, Qiaofeng Wan, Hongquan Wan, Wenbin Tuo, Florian Krammer, Zhiping Ye and Xiaoping Zhu, with collaborators at the USDA Agricultural Research Service, the FDA and the Icahn School of Medicine at Mount Sinai.
The research was supported by NIH grants AI146063 and AI190355, USDA NIFA Biosecurity grant 2025-39601-44631, the Maryland Agricultural Experiment Station, the Basil and Anne Hatziolos Scholarship Fund for Veterinary Medical Research, and the USDA ARS intramural research program.